The Valley Desk

ArticleBiotechnology and bioengineeringPublished

CRISPR-Editing of the Vero Cell Line Improves Processability of Live Virus Vaccines by Enabling Targeted Proteolysis of Fibronectin

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Merck & Co. Affiliation source

Institution
Merck & Co.

Publication record

Type
Article
Venue
Biotechnology and bioengineering
Published
Subject terms
Vero Cells; Animals; Fibronectins; Vaccines, Attenuated; Viral Vaccines; Proteolysis; CRISPR-Cas Systems; Gene Editing; Chlorocebus aethiops; Fibronectin; Ultrafiltration; Protein Removal
PubMed ID
40364716
Added to directory
Source checked

Report a correction or request removal